Zoekresultaten

Control of anthracnose (Colletotrichum gloeosporioides) growth in “Hass” avocado fruit using sachets filled with oregano oil-starch-capsules.

Active antifungal packaging is a technological solution for reducing the postharvest losses of fruits and vegetables associated with phytopathogens. Anthracnose (Colletotrichum gloeosporioides) is the principal fungus that causes post-harvest avocado fruit decay. In this study, antifungal sachets filled with oregano oil-starch capsules were prepared, and their active effects were demonstrated on Hass avocado fruits. Oregano oil (31 % of carvacrol) was encapsulated with corn starch by spray drying. Tyvek sachets (4 × 4 cm) filled with 80 (T1) and 160 mg (T2) of oregano oil-starch capsules (99.35 ± 1.86 mg g − 1) were fabricated. The antifungal effects of the sachets were tested in vitro and in vivo using a humidity chamber (90–95 % relative humidity (RH)) on fruits inoculated with anthracnose. The results showed that T1 and T2 inhibited 75.21 ± 2.81 and 100 % in vitro growth of anthracnose at 25 °C for 12 days. Furthermore, Hass avocado fruits stored in a humidity chamber at 25 °C for 6 days showed that only T2 significantly (p < 0.05) reduced the area of lesion produced by artificial inoculation of Hass avocado fruits with anthracnose. On average, the lesion area in the Hass avocado fruits treated with T2 was 13.94 % smaller than that in the control fruit.

Improved Efficacy of Oral Immunotherapy Using Non-Digestible Oligosaccharides in a Murine Cow's Milk Allergy Model

From teh UU repository: "Background: Oral immunotherapy (OIT) is a promising therapeutic approach to treat food allergic patients. However, there are some concerns regarding its safety and long-term efficacy. The use of non-digestible oligosaccharides might improve OIT efficacy since they are known to directly modulate intestinal epithelial and immune cells in addition to acting as prebiotics. Aim: To investigate whether a diet supplemented with plant-derived fructo-oligosaccharides (FOS) supports the efficacy of OIT in a murine cow's milk allergy model and to elucidate the potential mechanisms involved. Methods: After oral sensitization to the cow's milk protein whey, female C3H/HeOuJ mice were fed either a control diet or a diet supplemented with FOS (1% w/w) and received OIT (10 mg whey) 5 days a week for 3 weeks by gavage. Intradermal (i.d.) and intragastric (i.g.) challenges were performed to measure acute allergic symptoms and mast cell degranulation. Blood and organs were collected to measure antibody levels and T cell and dendritic cell populations. Spleen-derived T cell fractions (whole spleen-and CD25-depleted) were transferred to naive recipient mice to confirm the involvement of regulatory T cells (Tregs) in allergy protection induced by OIT + FOS. Results: OIT + FOS decreased acute allergic symptoms and mast cell degranulation upon challenge and prevented the challenge-induced increase in whey-specific IgE as observed in sensitized mice. Early induction of Tregs in the mesenteric lymph nodes (MLN) of OIT + FOS mice coincided with reduced T cell responsiveness in splenocyte cultures. CD25 depletion in OIT + FOS-derived splenocyte suspensions prior to transfer abolished protection against signs of anaphylaxis in recipients. OIT + FOS increased serum galectin-9 levels. No differences in short-chain fatty acid (SCFA) levels in the cecum were observed between the treatment groups. Concisely, FOS supplementation significantly improved OIT in the acute allergic skin response, %Foxp3+ Tregs and %LAP+ Th3 cells in MLN, and serum galectin-9 levels. Conclusion: FOS supplementation improved the efficacy of OIT in cow's milk allergic mice. Increased levels of Tregs in the MLN and abolished protection against signs of anaphylaxis upon transfer of CD25-depleted cell fractions, suggest a role for Foxp3+ Tregs in the protective effect of OIT + FOS. "

Pre-validatie voor duidelijkheid toepasbaarheid nieuwe 3V-testmethoden

State of the art on alternative methods to animal testing from an industrial point of view: ready for regulation?

Despite changing attitudes towards animal testing and current legislation to protect experimental animals, the rate of animal experiments seems to have changed little in recent years. On May 15–16, 2013, the In Vitro Testing Industrial Platform (IVTIP) held an open meeting to discuss the state of the art in alternative methods, how companies have, can, and will need to adapt and what drives and hinders regulatory acceptance and use. Several key messages arose from the meeting. First, industry and regulatory bodies should not wait for complete suites of alternative tests to become available, but should begin working with methods available right now (e.g., mining of existing animal data to direct future studies, implementation of alternative tests wherever scientifically valid rather than continuing to rely on animal tests) in non-animal and animal integrated strategies to reduce the numbers of animals tested. Sharing of information (communication), harmonization and standardization (coordination), commitment and collaboration are all required to improve the quality and speed of validation, acceptance, and implementation of tests. Finally, we consider how alternative methods can be used in research and development before formal implementation in regulations. Here we present the conclusions on what can be done already and suggest some solutions and strategies for the future.

Unmet needs in the management of Cervical Dystonia.

Cervical dystonia (CD) is a movement disorder which affects daily living of many patients. In clinical practice, several unmet treatment needs remain open. This article focuses on the four main aspects of treatment. We describe existing and emerging treatment approaches for CD, including botulinum toxin injections, surgical therapy, management of non-motor symptoms, and rehabilitation strategies. The unsolved issues regarding each of these treatments are identified and discussed, and possible future approaches and research lines are proposed.